Nov 30, 2010 by Brian Orelli, PhDA Witty Response to Pharma's R&D DilemmaGlaxo's CEO tells it like it is.
Nov 30, 2010 by Brian Orelli, PhDNice Data; Still a Long Wait for the PayoffKeryx's Zerenex passes its first phase 3 trial.
Nov 30, 2010 by Brian Orelli, PhDSoros Is Buying Health Care. Should You?Some but not all of his picks look good to me.
Nov 30, 2010 by Brian Orelli, PhDBetter Buy: Exact Sciences or Sequenom?A battle of the diagnostic test makers.
Nov 29, 2010 by Brian Orelli, PhDWhich Is a Better Buy: Complete Genomics or Pacific Biosciences?A DNA sequencing IPO showdown.
Nov 29, 2010 by Brian Orelli, PhDThere's Still Only OneMerck KGaA's oral MS drug delay is Novartis' gain.
Nov 29, 2010 by Brian Orelli, PhDHead to Head: Merck vs. ItselfMerck's HIV drug doesn't work as well when taken once daily.
Nov 24, 2010 by Brian Orelli, PhDThe Uninsured Are Killing Medical-Device MakersMedtronic is the latest to lower expectations.
Nov 24, 2010 by Brian Orelli, PhDYay! We Don't Have to Pay an 18.5% PenaltyGenzyme moves one step closer to a comeback.
Nov 24, 2010 by Brian Orelli, PhDProfit From the United States of DiabetesHalf the country could have an early form by 2020.
Nov 23, 2010 by Brian Orelli, PhDThe End of HIV as We Know It?Unfortunately, the financial opportunity isn't there.
Nov 22, 2010 by Brian Orelli, PhDLet's Call It a Partial VictoryMerck's Vytorin works better than a placebo. Big deal.
Nov 19, 2010 by Brian Orelli, PhDExelixis: Up 32% With Room to RunIt was only a phase 2 trial, after all.
Nov 19, 2010 by Brian Orelli, PhDOne Drug, Two Names, Two Wildly Different ProspectsAmgen double speaks for increased sales.
Nov 19, 2010 by Brian Orelli, PhDHow to Get Rich Buying This TrendWisdom from Dick Clark... yes, THAT Dick Clark. No ball drop required.
